Yazbeck R - Search Results

1

Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV.

Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS. Geier MS, et al. Among authors: yazbeck r. J Cell Physiol. 2005 Aug;204(2):687-92. doi: 10.1002/jcp.20333. J Cell Physiol. 2005. PMID: 15754331

2

Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice.

Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Yazbeck R, et al. Front Biosci. 2008 May 1;13:6850-8. doi: 10.2741/3193. Front Biosci. 2008. PMID: 18508699

3

Dipeptidyl peptidase expression during experimental colitis in mice.

Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Hörsten S, Holst JJ, Abbott CA. Yazbeck R, et al. Inflamm Bowel Dis. 2010 Aug;16(8):1340-51. doi: 10.1002/ibd.21241. Inflamm Bowel Dis. 2010. PMID: 20186930

4

Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis.

Yazbeck R, Howarth GS, Butler RN, Geier MS, Abbott CA. Yazbeck R, et al. J Cell Physiol. 2011 Dec;226(12):3219-24. doi: 10.1002/jcp.22682. J Cell Physiol. 2011. PMID: 21351101

5

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

Yazbeck R, Jaenisch SE, Abbott CA. Yazbeck R, et al. Biochem Pharmacol. 2021 Jun;188:114517. doi: 10.1016/j.bcp.2021.114517. Epub 2021 Mar 13. Biochem Pharmacol. 2021. PMID: 33722535 Free PMC article. Review.

6

Dipeptidyl peptidases and inflammatory bowel disease.

Abbott CA, Yazbeck R, Geier MS, Demuth HU, Howarth GS. Abbott CA, et al. Among authors: yazbeck r. Adv Exp Med Biol. 2006;575:155-62. doi: 10.1007/0-387-32824-6_16. Adv Exp Med Biol. 2006. PMID: 16700518 Review. No abstract available.

7

Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats.

Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS. Smith CL, et al. Among authors: yazbeck r. Nutr Cancer. 2008;60(6):757-67. doi: 10.1080/01635580802192841. Nutr Cancer. 2008. PMID: 19005975

8

Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA.

Roberts AL, Howarth GS, Liaw WC, Moretta S, Kritas S, Lymn KA, Yazbeck R, Tran C, Fletcher JM, Butler RN, Byers S. Roberts AL, et al. Among authors: yazbeck r. J Cell Physiol. 2009 May;219(2):259-64. doi: 10.1002/jcp.21682. J Cell Physiol. 2009. PMID: 19170061

9

Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU).

Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS. Whitford EJ, et al. Among authors: yazbeck r. Cancer Biol Ther. 2009 Mar 15;8(6):505-11. Epub 2009 Mar 15. Cancer Biol Ther. 2009. PMID: 19305160

10

Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

Yazbeck R, Howarth GS, Abbott CA. Yazbeck R, et al. Cytokine Growth Factor Rev. 2009 Apr;20(2):175-84. doi: 10.1016/j.cytogfr.2009.02.008. Epub 2009 Mar 25. Cytokine Growth Factor Rev. 2009. PMID: 19324585 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters